COMP <GO>
NAGE vs MDWD // EV/EBITDA & P/E VALUATION
Niagen Bioscience Inc. (NASDAQ) VS. MediWound Ltd. (NASDAQ) • 15-METRIC TALLY: NAGE 1
— MDWD 1
■ METRIC PARITY
LAST: $2.50 (-1.57%) • MKT CAP: $197.8M
valuation
12.2x
LAST: $13.86 (+2.21%) • MKT CAP: $178.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NAGE VS. MDWD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NAGE | MDWD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.80% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 12.2x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 6.83% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 12.60% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 13.40% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 29.90% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.40 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.9 | 55.1 | -12.23 | MDWD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 9.6x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $197.8M | $178.9M | $18.9M | NAGE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NAGE REV | MDWD REV | NAGE GROSS % | MDWD GROSS % | NAGE FCF | MDWD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $129.4M | — | 64.3% | — | $13.5M | — |
| FY 2024 | $99.6M | — | 61.8% | — | $12.1M | — |
| FY 2023 | $83.6M | — | — | — | $7.1M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NAGE // BETA —
MDWD // BETA —